Strides Pharma Science Limited (STAR.BO)

INR 702.0

(1.56%)

Market Cap (In INR)

64.69 Billion

Revenue (In INR)

40.51 Billion

Net Income (In INR)

-706.14 Million

Avg. Volume

19.96 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
570.9-1675.25
PE
-
EPS
-
Beta Value
0.73
ISIN
INE939A01011
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Badree Komandur
Employee Count
-
Website
https://www.strides.com
Ipo Date
2004-06-08
Details
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company has a strategic partnership with Orbicular Pharmaceutical Technologies Private Limited to develop, manufacture, and commercialize nasal sprays. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.